首页> 外文期刊>Journal of endocrinological investigation. >Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)
【24h】

Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet)

机译:SARS-CoV2 大流行传播对意大利神经内分泌肿瘤管理的影响:意大利神经内分泌肿瘤协会 (Itanet) 的报告

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Introduction The organization of the healthcare system has significantly changed after the recent COVID-19 outbreak, with a negative impact on the management of oncological patients. The present survey reports data collected by the Italian Association for Neuroendocrine Tumors on the management of patients with neuroendocrine neoplasia (NEN) during the pandemic dissemination. Methods A survey with 57 questions was sent to NEN-dedicated Italian centers regarding the management of patients in the period March 9, 2020, to May 9, 2020 Results The main modification in the centers' activity consisted of decreases in newly diagnosed NEN patients (- 76.8), decreases in performed surgical procedures (- 58), delays to starting peptide receptor radionuclide therapy (45.5), postponed/canceled follow-up examinations (26), and canceled multidisciplinary teams' activity (20.8). A low proportion of centers (< 10) reported having to withdraw systemic anti-tumor medical treatment due to concerns about the pandemic situation, whereas PRRT was withdrawn from no patients. Conclusion Although the COVID-19 outbreak induced the centers to reduce some important activities in the management of NEN patients, the Italian network was able to provide continuity in care without withdrawing anti-tumor treatment for the majority of patients.
机译:引言 在最近的 COVID-19 爆发后,医疗保健系统的组织发生了重大变化,对肿瘤患者的管理产生了负面影响。本调查报告了意大利神经内分泌肿瘤协会收集的关于大流行传播期间神经内分泌肿瘤 (NEN) 患者管理的数据。方法 向 NEN 专门的意大利中心发送了一份包含 57 个问题的调查,内容涉及 2020 年 3 月 9 日至 2020 年 5 月 9 日期间的患者管理 结果 中心活动的主要变化包括新诊断的 NEN 患者减少 (-76.8%)、外科手术减少 (-58%)、延迟开始肽受体放射性核素治疗 (45.5%), 推迟/取消后续检查(26%),取消多学科团队的活动(20.8%)。低比例的中心(<10%)报告说,由于担心大流行情况,不得不撤回全身抗肿瘤药物治疗,而PRRT则没有患者撤回。结论 尽管 COVID-19 的爆发促使中心减少了 NEN 患者管理中的一些重要活动,但意大利网络能够在不撤回大多数患者抗肿瘤治疗的情况下提供连续性护理。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号